HZNP News and Press, Horizon Therapeutics Public Limited Company From 08/08/23

Second-Quarter 2023 Results: -- Net Sales of $945.0 Million, Representing Year-Over-Year Growth of 11% Excluding Inflammation Medicines -- -- GAAP Net Income of $127.1 Million; Adjusted EBITDA of $320.4 Million -- -- TEPEZZA® (teprotumumab-trbw) Net Sales of $445.5 ...

2023-08-07 13:28:11 ET Horizon Therapeutics ( NASDAQ: HZNP ) is scheduled to announce Q2 earnings results on Tuesday, August 8th, before market open. The consensus EPS Estimate is $0.97 (-9.3% Y/Y) and the consensus Revenue Estimate is $873.51M (-0.3% Y/Y). Over the la...

2023-08-07 11:40:56 ET Summary Amgen's stock has rebounded by 10% and is showing improving fundamentals, with strong volume and revenue growth in core drugs and promising results in the pipeline. The company's recent earnings call confirmed the positive outlook, with record sales ...

2023-08-02 14:20:25 ET Amgen ( NASDAQ: AMGN ) is scheduled to announce Q2 2023 financial results on Thursday, August 3, after market close. The consensus EPS estimate is $4.49 (+3.4% Y/Y) and the consensus revenue estimate is $6.68B (+1.2% Y/Y). Over the last two years, ...

Fifty patient advocacy organizations from around the world awarded a $5,000 grant to address unique challenges faced in rare disease communities Horizon Therapeutics plc (Nasdaq: HZNP) today announced the 50 awardees from around the world selected to receive the 2023 #RAREis™ ...

- The Company continues to assess the full dataset; daxdilimab trials in alopecia areata, discoid lupus erythematosus and lupus nephritis ongoing – Horizon Therapeutics plc (Nasdaq: HZNP) today announced that its Phase 2 clinical trial evaluating daxdilimab for the treatment of...

2023-07-21 11:02:07 ET The new warning label on Horizon Therapeutics' ( NASDAQ: HZNP ) Tepezza  drug over potential hearing impairment is unlikely to have any impact on Horizon's planned sale to Amgen ( NASDAQ: AMGN ). "We doubt this has any impact on the AMGN-H...

2023-07-21 03:15:00 ET Summary The FTC’s recent push against some large M&A deals may ultimately limit the ability of major companies to take advantage of business development opportunities. In December 2022, the Federal Trade Commission (FTC) filed a lawsuit to block M...

2023-07-19 08:30:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. U.S. equities continue...

Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it will release its second-quarter 2023 financial results on Tuesday, Aug. 8, 2023, prior to the open of the U.S. financial markets. With the pending acquisition by Amgen Inc. and applicable securities laws, Horizon will not be host...